These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 30157803)

  • 61. A 20% dose reduction of the original CISCA/VB regimen allows better tolerance and similar survival rate in disseminated testicular non-seminomatous germ-cell tumors: final results of a phase III randomized trial.
    Fizazi K; Do KA; Wang X; Finn L; Logothetis CJ; Amato RJ
    Ann Oncol; 2002 Jan; 13(1):125-34. PubMed ID: 11863094
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Outcomes of relapsed/refractory extracranial germ cell tumors treated on conventional salvage chemotherapy without stem cell rescue: Experience from a tertiary cancer center.
    Ramanathan S; Prasad M; Vora T; Badira CP; Kembhavi S; Ramadwar M; Khanna N; Laskar S; Muckaden MA; Qureshi S; Banavali S; Chinnaswamy G
    Pediatr Blood Cancer; 2023 Apr; 70(4):e30179. PubMed ID: 36645132
    [TBL] [Abstract][Full Text] [Related]  

  • 63. [Chemotherapy for metastatic germ cell tumours of the testis].
    Culine S
    Rev Prat; 2007 Feb; 57(4):385-8. PubMed ID: 17455740
    [TBL] [Abstract][Full Text] [Related]  

  • 64. High-dose chemotherapy and autologous haematopoietic support in poor risk non-seminomatous germ-cell tumours: an effective first-line therapy with minimal toxicity.
    Decatris MP; Wilkinson PM; Welch RS; Metzner M; Morgenstern GR; Dougall M
    Ann Oncol; 2000 Apr; 11(4):427-34. PubMed ID: 10847461
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Outcome of 3-day bleomycin, etoposide and cisplatin chemotherapeutic regimen for patients with malignant ovarian germ cell tumours: a Taiwanese Gynecologic Oncology Group study.
    Chen CA; Lin H; Weng CS; Wen KC; Lu CH; Chou HH; Huang YF; Kang CY; Ho CM; Yu MH; Chou CY
    Eur J Cancer; 2014 Dec; 50(18):3161-7. PubMed ID: 25459394
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Outcomes of adolescent males with extracranial metastatic germ cell tumors: A report from the Malignant Germ Cell Tumor International Consortium.
    Shaikh F; Stark D; Fonseca A; Dang H; Xia C; Krailo M; Pashankar F; Rodriguez-Galindo C; Olson TA; Nicholson JC; Murray MJ; Amatruda JF; Billmire D; Stoneham S; Frazier AL
    Cancer; 2021 Jan; 127(2):193-202. PubMed ID: 33079404
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Equivalence of three or four cycles of bleomycin, etoposide, and cisplatin chemotherapy and of a 3- or 5-day schedule in good-prognosis germ cell cancer: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group and the Medical Research Council.
    de Wit R; Roberts JT; Wilkinson PM; de Mulder PH; Mead GM; Fosså SD; Cook P; de Prijck L; Stenning S; Collette L
    J Clin Oncol; 2001 Mar; 19(6):1629-40. PubMed ID: 11250991
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Importance of bleomycin in combination chemotherapy for good-prognosis testicular nonseminoma: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group.
    de Wit R; Stoter G; Kaye SB; Sleijfer DT; Jones WG; ten Bokkel Huinink WW; Rea LA; Collette L; Sylvester R
    J Clin Oncol; 1997 May; 15(5):1837-43. PubMed ID: 9164193
    [TBL] [Abstract][Full Text] [Related]  

  • 69. The treatment of metastatic germ-cell testicular tumours with bleomycin, etoposide and cis-platin (BEP).
    Peckham MJ; Barrett A; Liew KH; Horwich A; Robinson B; Dobbs HJ; McElwain TJ; Hendry WF
    Br J Cancer; 1983 May; 47(5):613-9. PubMed ID: 6189504
    [TBL] [Abstract][Full Text] [Related]  

  • 70. High-dose chemotherapy with autologous stem cell support in patients with metastatic non-seminomatous testicular cancer - a report from the Swedish Norwegian Testicular Cancer Group (SWENOTECA).
    Haugnes HS; Laurell A; Stierner U; Bremnes RM; Dahl O; Cavallin-Ståhl E; Cohn-Cedermark G
    Acta Oncol; 2012 Feb; 51(2):168-76. PubMed ID: 22175254
    [TBL] [Abstract][Full Text] [Related]  

  • 71. The effect of pulmonary function testing on bleomycin dosing in germ cell tumours.
    Roncolato FT; Chatfield M; Houghton B; Toner G; Stockler M; Thomson D; Friedlander M; Gurney H; Rosenthal M; Grimison P;
    Intern Med J; 2016 Aug; 46(8):893-8. PubMed ID: 27305276
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Protocol of DREAM3R: DuRvalumab with chEmotherapy as first-line treAtment in advanced pleural Mesothelioma-a phase 3 randomised trial.
    Kok PS; Forde PM; Hughes B; Sun Z; Brown C; Ramalingam S; Cook A; Lesterhuis WJ; Yip S; O'Byrne K; Pavlakis N; Brahmer J; Anagnostou V; Ford K; Fitzpatrick K; Bricker A; Cummins MM; Stockler M; Nowak AK;
    BMJ Open; 2022 Jan; 12(1):e057663. PubMed ID: 35078853
    [TBL] [Abstract][Full Text] [Related]  

  • 73. The contemporary role of chemotherapy for advanced testis cancer: a systematic review of the literature.
    Calabrò F; Albers P; Bokemeyer C; Martin C; Einhorn LH; Horwich A; Krege S; Schmoll HJ; Sternberg CN; Daugaard G
    Eur Urol; 2012 Jun; 61(6):1212-21. PubMed ID: 22464311
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Effectiveness and Safety of Pegfilgrastim in BEP Treatment for Patients with Germ Cell Tumor.
    Iwamoto H; Izumi K; Natsagdorj A; Makino T; Nohara T; Shigehara K; Kadono Y; Mizokami A
    In Vivo; 2018; 32(4):899-903. PubMed ID: 29936477
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Prognostic Factors and Treatment Results After Bleomycin, Etoposide, and Cisplatin in Germ Cell Cancer: A Population-based Study.
    Kier MG; Lauritsen J; Mortensen MS; Bandak M; Andersen KK; Hansen MK; Agerbaek M; Holm NV; Dalton SO; Johansen C; Daugaard G
    Eur Urol; 2017 Feb; 71(2):290-298. PubMed ID: 27649970
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Comparison of two standard chemotherapy regimens for good-prognosis germ-cell tumours: a randomised trial. Australian and New Zealand Germ Cell Trial Group.
    Toner GC; Stockler MR; Boyer MJ; Jones M; Thomson DB; Harvey VJ; Olver IN; Dhillon H; McMullen A; Gebski VJ; Levi JA; Simes RJ
    Lancet; 2001 Mar; 357(9258):739-45. PubMed ID: 11253966
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Predictors of outcome in patients with advanced nonseminomatous germ cell testicular tumors.
    Yetisyigit T; Babacan N; Urun Y; Seber ES; Cihan S; Arpaci E; Yildirim N; Aksoy S; Budakoglu B; Zengin N; Oksuzoglu B; Yalcin BC; Alkis N
    Asian Pac J Cancer Prev; 2014; 15(2):831-5. PubMed ID: 24568504
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Survival and toxicity in patients with disseminated germ cell cancer aged 40 years and older.
    Thomsen FB; Bandak M; Thomsen MF; Lauritsen J; Christensen IJ; Daugaard G
    Cancer; 2014 Jan; 120(1):43-51. PubMed ID: 24108413
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Current pharmacotherapy for testicular germ cell cancer.
    Alsdorf W; Seidel C; Bokemeyer C; Oing C
    Expert Opin Pharmacother; 2019 May; 20(7):837-850. PubMed ID: 30849243
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.